English Español VALUES QUALITY OUR TEAM PHARMACOVIGILANCE CONTACT ABOUT US BUSINESS DEVELOPMENT NUTRA ESSENTIAL OTC PRODUCTS 31 Oct 2018 / by farmalider / in NEWS Farmalider, a pharmaceutical company that specializes in innovating with molecules that have lost their patent, has taken another step in its globalization by opening a new office in Miami (USA). This latest location expands on those the company already has in Barcelona (Spain), Istanbul (Turkey) and Auckland (New Zealand). The growth plan began eight years ago. Farmalider’s Turkish subsidiary is now the group’s most profitable location. By bringing Miami into the picture, Farmalider hopes it will provide a springboard into the Latin America market where, as Chairman José Luis Berenguer states, “We have created partnerships with several companies in order to diversify risk.” As well as going global, one of Farmalider’s short-term aims is to float on the London Alternative Investment market (AIM). “In the United Kingdom, this is a very important market and includes over 1500 more relevant companies. Nobody who has been around for 25 years enters the Spanish Alternative Stock Market (MAB), which is made up of smaller companies. MAB investors are looking for risk and we are not a risky company, so the MAB didn’t fit the bill for us,” Berenguer explains. Today, Farmalider is comprised of 14 companies. The newest are Ophta Pharma and Ophta Biotech—ophthalmology and intraocular contact lens specialists—for which Farmalider is now seeking to bring in an international pharmaceuticals company to optimize sales. Farmalider, S.A. C/La Granja, 1 28108 Alcobendas, Madrid, Spain Tel: 91 661 23 35, C.I.F: A78285301 © Copyright 2020. Farmalider Group. All Rights Reserved. Legal Notice

English Español VALUES QUALITY OUR TEAM PHARMACOVIGILANCE CONTACT ABOUT US BUSINESS DEVELOPMENT NUTRA ESSENTIAL OTC PRODUCTS The Pharmacovigilance Department tracks and analyses permanently the information related to our medicines received from different sources such us Healthcare professionals and patients. If you wish to report a suspected adverse reaction to any medicine of Farmalider Group, please contact us by email to farmacovigilancia@farmalider.com and our Pharmacovigilance Department will collect this information and will contact you shortly. You can also contact us by phone or fax: Tel: +34 916 612 335 Fax: + 34 916 610 442 In compliance of the current law with respect to protection of personal data, we inform you that your personal data will be processed confidentiality with the aim of “Management of adverse reactions/special situation of the medication as well as clinical incidents or events about FARMALIDER’s products. For further information about our Policy about Protection of Personal Data, please, consult our Privacy Policy in pharmacovigilance. Farmalider, S.A. C/La Granja, 1 28108 Alcobendas, Madrid, Spain Tel: 91 661 23 35, C.I.F: A78285301 © Copyright 2020. Farmalider Group. All Rights Reserved. Legal Notice